TP53 mutations also play a pivotal role in the histologic transformation to small-cell lung cancer (SCLC), a mechanism of resistance to first- and second-generation EGFR-TKIs known since 2011 [62]. This evidence concerns the gene EGFR and small cell lung carcinoma.